Kyowa Kirin
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Japan · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
Otemachi Financial City Grand Cube 1-9-2...Phone Number
+81 352057200Website
www.kyowakirin.comRevenue
$3 BillionStock Symbol
KYKOFIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
6
5
1
1
1
1
About Kyowa Kirin
Kyowa Kirin is a global specialty pharmaceutical company focused on antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. They are headquartered in Tokyo, Japan.Explore more
Kyowa Kirin Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kyowa Kirin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Kyowa Kirin is spiking on competitors!
Check if Kyowa Kirin has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Kyowa Kirin
Click to see if Kyowa Kirin had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Kyowa Kirin, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Kyowa Kirin launches new products
Earning: See what the market has to say on Kyowa Kirin recently announced quarterly report
Funding: Get notified immidiatlly once Kyowa Kirin has new funding data
Recommended Actions
Reach out to Masked Content who joined Kyowa Kirin as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Kyowa Kirin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kyowa Kirin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kyowa Kirin.
Kyowa Kirin Tech Stack
A closer look at the technologies used by Kyowa Kirin
Most Recent Scoops
Person-Based
Research & Development, Pharmaceuticals
Person-Based
Financial Planning
Person-Based
Earnings, Financial Reporting, Finance
Person-Based
Research & Development, Corporate Strategy
Person-Based
Earnings, Finance
Kyowa Kirin News & Media
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster PresentationKura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
PRINCETON, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved a dosing update to the CRYSVITA® (burosumab-twza) Prescribing Information for adults living with X-linked hypophosphatemia (XLH), a rare, progressive, genetic disease that impacts the bones and muscles in both children and adults. Healthcare providers now have the option to increase the dose and frequencyKura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kyowa Kirin
Sign Up For FreeTo access detailed company insights
Kyowa Kirin is a global specialty pharmaceutical company focused on antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. They are headquartered in Tokyo, Japan.... Read More
